Guanfacine extended-release tablets (Intuniv), a nonstimulant selective alpha2A-adrenergic receptor agonist for attention-deficit/ hyperactivity disorder

P and T

Volumn 35, Issue 8, 2010, Pages 448-451

  Cruz, Martin P ^a,b,c,d  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b HAMPTON UNIVERSITY   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d Hampton VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; GUANFACINE; INTUNIV; KETOCONAZOLE; PLACEBO; UNCLASSIFIED DRUG; VALPROIC ACID;

APPETITE DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; BLOOD PRESSURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DIZZINESS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXTENDED DRUG RELEASE; FATIGUE; HEADACHE; HUMAN; HYPOTENSION; IRRITABLE COLON; MORNING DOSAGE; NAUSEA; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TABLET FORMULATION; UPPER ABDOMINAL PAIN; XEROSTOMIA;

EID: 77957151677     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders, 4th rev. ed. (DSM-IV-TR). Washington, D.C.: American Psychiatric Association, 2000.
2. American Academy of Pediatrics clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000;105(5):1158-1170.
3. National Health Interview Survey, 2006 (machine-readable data file and documentation). Hyattsville, Md.: National Center for Health Statistics; 2007. Available at: www.cdc.gov/nchs/nhis.htm.
4. Miller A, Lee SK, Raina P, et al. A review of therapies for attention deficit hyperactivity disorder. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1998; RFP #ADHD-1196. Available at: www.ccohta.ca/main-e. html. Accessed June 29, 2010.
5. Schachter HM, Pham B, King J, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. Can Med Assoc J 2001;165(11):1475- 1488. (Pubitemid 34060190)
6. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999;56(12):1073- 1086.
7. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46(7):894-921.
8. Intuniv (guanfacine extended-release oral tablets), product information. Wayne, Pa.: Shire; 2010.
9. Tenex (guanfacine HCl tablets), product information. Bridgewater, N.J.: Reddy; 2006.
10. Tenex (guanfacine), product information. Richmond, Va.: A.H. Robins Co.; 1996.
11. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008;121(1):e73-e84.
12. Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19(3):215-226.
13. Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 2008;122(2):451-453.
14. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: A scientific statement from the American Heart Association Congenital Cardiac Defects Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular Nursing. Circulation 2008;117:2407-2423. (Pubitemid 351653546)
15. Bennett WM, Aronoff GR, Golper TA, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults, 3rd ed. Philadelphia: American College of Physicians;1994.
16. Kirch W, Kohler H, Braun W, et al. The influence of renal function on plasma concentration, urinary excretion, and antihypertensive effect of guanfacine. Clin Pharmacokinet 1980;5(5):476-483. (Pubitemid 11249025)
17. Kiechel JR: Pharmacokinetics of guanfacine in patients with impaired renal function and in some elderly patients. Am J Cardiol 1986;57(9):18E-21E.
18. Kiechel JR. Pharmacokinetics and metabolism of guanfacine in man: A review. Br J Clin Pharmacol 1980;10(Suppl 1):25S-32S.
19. Guanfacine extended-release tablets. Available at: www.shirepricing.com/ Documents/INTUNIV-long-form.pdf. Accessed July 8, 2010; and McKesson.